Journal of Biochemistry and Biotechnology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Rapid Communication - Journal of Biochemistry and Biotechnology (2025) Volume 8, Issue 1

Gene Assays for Identifying Biomarkers: Advancing Precision Medicine

Samuel Green*

Department of Immunology, North view University, United States

*Corresponding Author:
Samuel Green
Department of Immunology
North view University, United States
E-mail: samuel.green@northview.edu

Received: 09-Feb-2025, Manuscript No. AABB-25-161097; Editor assigned: 10-Feb-2025, Pre QC No. AABB-25-161097 (PQ); Reviewed: 22-Feb-2025, QC No. AABB-25-161097;
Revised: 24-Feb-2025, Manuscript No. AABB-25-161097 (R); Published: 28-Feb-2025, DOI:10.35841/aabb-8.1.249

Citation: Green S. Gene Assays for Identifying Biomarkers: Advancing Precision Medicine. J Biochem Biotech 2025; 8(1):249.

Visit for more related articles at Journal of Biochemistry and Biotechnology

Introduction

The field of precision medicine is revolutionizing healthcare by enabling treatments tailored to individual patients based on their genetic makeup, environment, and lifestyle. At the core of this approach are biomarkers—biological molecules that indicate normal or pathological processes, or the response to therapeutic interventions. Gene assays play a crucial role in identifying these biomarkers, which can then be used to diagnose diseases, predict treatment responses, and monitor disease progression. This article explores the importance of gene assays in biomarker discovery and their impact on advancing precision medicine [1].

Gene assays are laboratory techniques that measure the expression levels, mutations, or variations in specific genes. These assays provide insights into the molecular mechanisms of diseases and can be used to identify potential therapeutic targets. Common types of gene assays include quantitative polymerase chain reaction (qPCR), microarrays, next-generation sequencing (NGS), and RNA sequencing (RNA-seq). Each of these methods has its advantages and applications, depending on the type of biomarker being studied and the clinical question being addressed [2].

Biomarkers are key to the development of precision medicine because they help physicians identify which treatments will be most effective for individual patients. In oncology, for example, biomarkers like HER2 in breast cancer or EGFR mutations in lung cancer guide the selection of targeted therapies that are more likely to succeed in specific patient populations. Gene assays allow researchers to identify these genetic signatures and use them to tailor therapies, improving patient outcomes and reducing unnecessary side effects [3].

Cancer research has greatly benefited from the use of gene assays in biomarker discovery. Microarray technology, for instance, has enabled researchers to profile the gene expression patterns of different cancer types, leading to the identification of biomarkers that predict disease prognosis and treatment response. For example, the Oncotype DX test analyzes the expression of 21 genes to assess the likelihood of breast cancer recurrence and guide treatment decisions. Similarly, NGS has uncovered numerous genetic mutations and alterations that serve as biomarkers in various cancers, opening the door to targeted therapies [4].

In addition to cancer, gene assays are being used to identify biomarkers for cardiovascular diseases. For instance, the detection of genetic variants associated with high cholesterol levels (e.g., mutations in the LDLR gene) can help identify individuals at risk for heart disease and guide the use of cholesterol-lowering drugs like statins. Gene assays also aid in the discovery of biomarkers for conditions like heart failure and hypertension, allowing for more precise diagnosis and personalized treatment strategies [5].

Neurological diseases such as Alzheimer's and Parkinson's present unique challenges due to the complexity of the brain and the difficulty in accessing brain tissue for study. However, gene assays are helping to identify genetic biomarkers associated with these conditions. For example, certain gene mutations, such as those in the APOE gene, have been linked to an increased risk of developing Alzheimer's disease. Gene expression assays are also being used to study the genetic underpinnings of neurodegenerative diseases, offering new opportunities for early diagnosis and targeted interventions [6].

RNA sequencing (RNA-seq) has emerged as a powerful tool for identifying biomarkers in precision medicine. Unlike traditional methods that focus on known genes, RNA-seq provides a comprehensive view of the transcriptome, revealing both known and novel RNA species. This approach has been particularly useful in identifying biomarkers for rare diseases and cancers with complex genetic profiles. For instance, RNA-seq has identified fusion genes and alternative splicing events that serve as biomarkers for specific cancer subtypes, leading to more targeted treatments [7].

Gene assays are also crucial in the fight against infectious diseases. During the COVID-19 pandemic, PCR-based gene assays were used to detect the presence of the SARS-CoV-2 virus, enabling rapid diagnosis and isolation of infected individuals. Beyond diagnostics, gene assays can identify biomarkers that predict disease severity or response to treatment, helping to inform clinical decisions. For example, certain gene variants have been associated with increased susceptibility to severe COVID-19, guiding the development of targeted therapies and preventive measures [8].

While gene assays have advanced biomarker discovery, they are not without challenges. One major limitation is the complexity of interpreting large amounts of data generated by high-throughput techniques like NGS and RNA-seq. Additionally, the heterogeneity of diseases, particularly in cancer, means that not all biomarkers will be applicable to every patient. Standardizing gene assay protocols and improving bioinformatics tools for data analysis are critical for overcoming these challenges and ensuring the clinical utility of biomarkers [9].

The future of gene assays in precision medicine is bright, with continued advancements in technology and bioinformatics driving the discovery of new biomarkers. Innovations like single-cell sequencing and CRISPR-based gene assays are providing even greater resolution in studying gene expression and genetic variations, offering new possibilities for personalized treatment approaches. As gene assays become more integrated into clinical practice, they will play an increasingly central role in diagnosing diseases, predicting treatment outcomes, and advancing precision medicine [10].

Conclusion

Gene assays have become an essential tool in biomarker discovery, enabling the identification of genetic signatures that drive disease and inform therapeutic strategies. From cancer to cardiovascular and neurological diseases, gene assays have provided valuable insights into disease mechanisms and opened the door to personalized medicine. As technology continues to evolve, gene assays will remain at the forefront of precision medicine, improving patient care through the identification of actionable biomarkers.

References

  1. Perou CM, Sørlie T, Eisen MB. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52.

    2. Indexed at, Google Scholar, Cross Ref

  2. Paik S, Shak S, Tang G. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-26.

    3. Indexed at, Google Scholar, Cross Ref

  3. Stoughton RB. Applications of DNA microarrays in biology. Annu Rev Biochem. 2005;74(1):53-82.

    4. Indexed at, Google Scholar, Cross Ref

  4. Kathiresan S, Srivastava D. Genetics of human cardiovascular disease. Cell. 2012;148(6):1242-57.

    5. Indexed at, Google Scholar, Cross Ref

  5. Dilliott AA, Abdelhady A, Sunderland KM. Contribution of rare variant associations to neurodegenerative disease presentation. NPJ. 2021;6(1):80.

    6. Indexed at, Google Scholar, Cross Ref

  6. Hong M, Tao S, Zhang L. RNA sequencing: new technologies and applications in cancer research. J Hematol Oncol. 2020;13:1-6.

    7. Indexed at, Google Scholar, Cross Ref

  7. Danielsson K, Mun LJ, Lordemann A. Next-generation sequencing applied to rare diseases genomics. Expert Rev Mol Diagn. 2014;14(4):469-87.

    8. Indexed at, Google Scholar, Cross Ref

  8. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006;113(19):2335-62.

    9. Indexed at, Google Scholar, Cross Ref

  9. Di Carlo E, Sorrentino C. State of the art CRISPR-based strategies for cancer diagnostics and treatment. Biomarker Res. 2024;12(1):156.

    10. Indexed at, Google Scholar, Cross Ref

  10. Slikker Jr W. Biomarkers and their impact on precision medicine. Exp Biol Med. 2017;243(3):211.

    11. Indexed at, Google Scholar, Cross Ref

Get the App